316 related articles for article (PubMed ID: 26098749)
21. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
22. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
[TBL] [Abstract][Full Text] [Related]
23. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
24. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
25. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
26. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
Kim EK; Kim KA; Lee CY; Shim HS
PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
[TBL] [Abstract][Full Text] [Related]
27. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.
Sholl LM; Aisner DL; Varella-Garcia M; Berry LD; Dias-Santagata D; Wistuba II; Chen H; Fujimoto J; Kugler K; Franklin WA; Iafrate AJ; Ladanyi M; Kris MG; Johnson BE; Bunn PA; Minna JD; Kwiatkowski DJ;
J Thorac Oncol; 2015 May; 10(5):768-777. PubMed ID: 25738220
[TBL] [Abstract][Full Text] [Related]
28. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
[TBL] [Abstract][Full Text] [Related]
29. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
Park S; Koh J; Kim DW; Kim M; Keam B; Kim TM; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
[TBL] [Abstract][Full Text] [Related]
30. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
32. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y
Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499
[TBL] [Abstract][Full Text] [Related]
33. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
34. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
35. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
[TBL] [Abstract][Full Text] [Related]
36. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
37. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Song Z; Yu X; Cheng G; Zhang Y
J Transl Med; 2016 Jun; 14(1):188. PubMed ID: 27342566
[TBL] [Abstract][Full Text] [Related]
38. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
Song Z; Wang X; Zheng Y; Su H; Zhang Y
Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
[TBL] [Abstract][Full Text] [Related]
39. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
40. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
